Evidence map›Paper›PMID 38486190›Full record

SynthesisBMC gastroenterology2024

Circulatory resistin levels in inflammatory bowel disease: a systematic review and meta-analysis.

Amir Hossein Behnoush, Seyede Parmis Maroufi, Tara Reshadmanesh, Yasmin Mohtasham Kia, Mitra Norouzi, Seyedeh Mina Mohammadi, Aleksandra Klisic, Amirmohammad Khalaji

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Amir Hossein BehnoushSchool of Medicine, Tehran University of Medical Sciences, Poursina St., Keshavarz Blvd, 1417613151, Tehran, Iran. amirhossein.behnoush@gmail.com.
Seyede Parmis MaroufiNeurosurgical Research Network, Universal Scientific Education and Research Network, Tehran University of Medical Sciences, Tehran, Iran.
Tara ReshadmaneshStudent Research Center, School of Medicine, Zanjan University of Medical Science, Zanjan, Iran.
Yasmin Mohtasham KiaSchool of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mitra NorouziFaculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Seyedeh Mina MohammadiIslamic Azad University Tehran Faculty of Medicine, Tehran, Iran.
Aleksandra KlisicFaculty of Medicine, University of Montenegro, Podgorica, Montenegro.
Amirmohammad KhalajiSchool of Medicine, Tehran University of Medical Sciences, Poursina St., Keshavarz Blvd, 1417613151, Tehran, Iran.
Tehran University of Medical Sciences · IRIran University of Medical Sciences · IRIslamic Azad University Medical Branch of Tehran · IRShahid Beheshti University · IRUniversal Scientific Education and Research Network · IRUniversity of Montenegro · ME

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic relapsing-remitting systemic disease of the gastrointestinal tract with rising incidence. Studies have shown that adipocytes play a crucial role in patients with IBD by actively participating in systemic immune responses. The present study was designed to investigate the correlation between the circulatory levels of resistin, as an adipokine, and active and remission phases of IBD in comparison with healthy controls.

methodsRelevant articles were retrieved from PubMed, Embase, the Web of Science, and Scopus from inception until June 2023. Estimation of the standardized mean difference (SMD) and 95% confidence interval (CI) for comparison of plasma/serum resistin levels between IBD patients, patients in remission, and healthy controls were conducted through random-effect meta-analysis.

resultsA total of 19 studies were included, assessing 1836 cases. Meta-analysis indicated that generally, serum/plasma resistin levels were higher in IBD patients in comparison with healthy controls (SMD 1.33, 95% CI 0.58 to 2.08, p-value < 0.01). This was true for each of the UC and CD separate analyses, as well. Moreover, it was shown that higher serum/plasma resistin levels were detected in the active phase of IBD than in the remission phase (SMD 1.04, 95% CI 0.65 to 1.42, p-value = 0.01). Finally, higher serum/plasma resistin levels were found in the remission phase compared to healthy controls (SMD 0.60, 95% CI 0.15 to 1.06, p-value < 0.01).

conclusionThe results of this systematic review and meta-analysis support the conclusion that circulating resistin levels are increased in IBD (both UC and CD). Also, higher resistin levels were recorded in the remission phase of IBD in comparison with healthy controls. This indicates that further studies may provide valuable insights into the role of resistin in the pathogenesis of IBD.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesHumansResistinResistinCrohnInflammatory Bowel DiseaseMeta-analysisResistinSystematic ReviewUlcerative Colitis

Identifiers

PMID38486190
PMCPMC10941394
OpenAlexW4392804857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.